Literature DB >> 10873679

Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction.

T Saito1, I W Rodger, F Hu, H Shennib, A Giaid.   

Abstract

Induction of cyclooxygenase-2 (COX-2) in ischemic myocardium is thought to increase the production of proinflammatory prostanoids and contribute significantly to the ischemic inflammation. Left ventricular myocardial infarction (MI) was created by ligating the left coronary artery in Lewis rats. Hemodynamic measurements at 4 weeks showed better cardiac function in the group treated with a selective COX-2 inhibitor (DFU; 5 mg/kg/day) for 2 weeks after induction of MI compared to the vehicle treated group. These results suggest that induction of COX-2 contributes to myocardial dysfunction, and that selective inhibition of COX-2 could constitute an important therapeutic target for the treatment of MI. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10873679     DOI: 10.1006/bbrc.2000.3010

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Cyclo-oxygenase-2 (COX-2) expression at the site of recent myocardial infarction: friend or foe?

Authors:  A Abbate; D Santini; G G L Biondi-Zoccai; S Scarpa; F Vasaturo; G Liuzzo; R Bussani; F Silvestri; F Baldi; F Crea; L M Biasucci; A Baldi
Journal:  Heart       Date:  2004-04       Impact factor: 5.994

Review 2.  Targeting inflammation: impact on atherothrombosis.

Authors:  Maria Giulia Marini; Chiara Sonnino; Marco Previtero; Luigi M Biasucci
Journal:  J Cardiovasc Transl Res       Date:  2013-12-11       Impact factor: 4.132

3.  Cyclooxygenase-2 inhibition improves antioxidative defense during experimental hypercholesterolemia.

Authors:  Sagheer Ahmed; Saima Gul; Humera Gul; Muhammad Zia-Ul-Haq; Sezai Ercisli
Journal:  Bosn J Basic Med Sci       Date:  2014-05       Impact factor: 3.363

4.  Preserved heart function and maintained response to cardiac stresses in a genetic model of cardiomyocyte-targeted deficiency of cyclooxygenase-2.

Authors:  Kyriakos N Papanicolaou; John M Streicher; Tomo-O Ishikawa; Harvey Herschman; Yibin Wang; Kenneth Walsh
Journal:  J Mol Cell Cardiol       Date:  2010-04-24       Impact factor: 5.000

5.  Lack of microsomal prostaglandin E synthase-1 reduces cardiac function following angiotensin II infusion.

Authors:  Pamela Harding; Xiao-Ping Yang; Quan He; Margot C Lapointe
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-12-30       Impact factor: 4.733

6.  Infiltration of inflammatory cells plays an important role in matrix metalloproteinase expression and activation in the heart during sepsis.

Authors:  Jimena Cuenca; Paloma Martín-Sanz; Alberto M Alvarez-Barrientos; Lisardo Boscá; Nora Goren
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

Review 7.  Selective cyclo-oxygenase-2 inhibitors and myocardial infarction: how strong is the link?

Authors:  Laurence G Howes; Henry Krum
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 8.  Benefit-risk assessment of rofecoxib in the treatment of osteoarthritis.

Authors:  Helmut Schmidt; Barry G Woodcock; Gerd Geisslinger
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

9.  Inhibition of 5-lipoxygenase by zileuton in a rat model of myocardial infarction.

Authors:  Leyla Abueid; Ünal Uslu; Alev Cumbul; Ayliz Velioğlu Öğünç; Feriha Ercan; İnci Alican
Journal:  Anatol J Cardiol       Date:  2016-11-10       Impact factor: 1.596

10.  Selective cyclooxygenase-2 inhibition protects against myocardial damage in experimental acute ischemia.

Authors:  Alberto Carnieto; Paulo Magno Martins Dourado; Protásio Lemos da Luz; Antonio Carlos Palandri Chagas
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.